In 2018, Socinski et al., demonstrated that atezolizumab plus bevacizumab significantly improved PFS and OS in patients with metastatic NS-NSCLC, regardless of PD-L1 expression and EGFR or ALK gene alteration status [80]. Here, ALK is linked to non-small cell lung carcinoma.